Earlier this month the Institute for Gene Therapies submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on their Fiscal Year 2023 Medicare Inpatient Prospective Payment Systems (IPPS) proposed rule.
IGT’s comments provided feedback on the Agency’s request for public comment on how rare disease and gene therapies should be incorporated in the MS-DRG reimbursement system and also reiterated and expanded upon IGT’s request that CMS develop an enhanced gene therapy NTAP pathway to facilitate rapid provider and patient access to gene therapies.
IGT is urging CMS to…
Establish an MS-DRG for each approved gene therapy in the inpatient setting, which would help ensure that the IPPS does not inhibit access to, or the future innovation of, gene therapies.
Establish an enhanced NTAP pathway specific to gene therapies, which is critical for providing a predictable and streamlined process for rapid patient access to cutting-edge gene therapies.
Read the full comment letter HERE.